23 Participants Needed

GentleWave System for Apical Periodontitis

FT
Overseen ByFabricio Teixeira, DDS,MS,PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The purpose of this 12-month prospective cohort study is to evaluate post-operatory pain, patient satisfaction, and treatment outcomes (i.e., healing) when the newly-developed, 510k FDA-approved multisonic energy GentleWAve System (Sonendo, Inc., Laguna Hills, CA) is used in complex root canal procedures.

Do I need to stop my current medications for the trial?

The trial does not specify if you need to stop taking your current medications, but it does exclude people taking corticosteroids.

What data supports the effectiveness of the GentleWave System treatment for apical periodontitis?

Research shows that the GentleWave System is effective in cleaning root canals and removing biofilm, which are key to successful healing after root canal treatments. Studies found it to be more effective than traditional methods in reducing biofilm and improving healing rates in molars.12345

Is the GentleWave System safe for use in humans?

There is no specific safety data available for the GentleWave System in the provided research articles.678910

How does the GentleWave System treatment differ from other treatments for apical periodontitis?

The GentleWave System is unique because it uses high-velocity degassed irrigants and broad-spectrum sound energy to clean root canals more effectively than traditional methods, resulting in better removal of biofilm and higher tissue dissolution rates.123511

Research Team

FT

Fabricio Teixeira, DDS,MS,PhD

Principal Investigator

University of Iowa College of Dentistry

Eligibility Criteria

This trial is for adults over 18 who can read and speak English, have specific types of molars with a diagnosis of pulp necrosis and apical periodontitis, and can attend follow-ups. It's not for those with untreated gum disease, poor dental visit attendance, or students/trainees linked to the research team.

Inclusion Criteria

Current radiograph available (or done at screening, as needed)
My tooth problem is with a lower back molar.
My dental scan shows I have root tip inflammation.
See 4 more

Exclusion Criteria

My tooth has had previous treatment like cleaning out the pulp.
I experience facial pain not related to my teeth.
Supervised by the Principal Investigator or a member of the research team
See 13 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive root canal therapy using the Sonendo GentleWave System

1-2 weeks
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months
Multiple visits at 2 days, 1 week, 2 weeks, 6 months, and 12 months post-baseline

Treatment Details

Interventions

  • GentleWave System
Trial Overview The study tests the GentleWave System in root canal treatments over a year. It focuses on pain after surgery, patient satisfaction, and how well the treatment heals infected root canals compared to traditional methods.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Sonendo GentleWaveExperimental Treatment1 Intervention
Every participant will receive the same experimental treatment, which is root canal therapy using the Sonendo GentleWave System.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Iowa

Lead Sponsor

Trials
486
Recruited
934,000+

Findings from Research

In a six-month clinical study involving 89 patients, the GentleWave® System demonstrated a high cumulative success rate of 97.4% for healing molars after root canal treatment.
Two key factors associated with successful healing were identified: the presence of apical periodontitis before treatment and the completion of the procedure in a single visit, highlighting the importance of these factors in treatment outcomes.
Six-month healing success rates after endodontic treatment using the novel GentleWave™ System: The pure prospective multi-center clinical study.Sigurdsson, A., Le, KT., Woo, SM., et al.[2020]
In a study involving 89 patients, the GentleWave System demonstrated a high cumulative success rate of 97.3% for healing molars after endodontic therapy over a 12-month period.
The system was particularly effective for treating irreversible pulpitis, achieving a success rate of 98.4%, and only 3.8% of patients reported moderate postoperative pain, indicating a favorable safety profile.
12-month Healing Rates after Endodontic Therapy Using the Novel GentleWave System: A Prospective Multicenter Clinical Study.Sigurdsson, A., Garland, RW., Le, KT., et al.[2022]
The GentleWave System (GWS) demonstrated a significantly higher cleaning efficacy in root canals compared to conventional rotary instrumentation, achieving a 97.2% cleaning rate in certain canal regions versus 67.8% with traditional methods.
In a study involving 45 freshly extracted molars, the GWS effectively reduced residual debris in the mesiobuccal and mesiolingual canals, indicating its potential to improve endodontic treatment outcomes and reduce the risk of persistent infection.
Evaluation of Root Canal Debridement of Human Molars Using the GentleWave System.Molina, B., Glickman, G., Vandrangi, P., et al.[2017]

References

Six-month healing success rates after endodontic treatment using the novel GentleWave™ System: The pure prospective multi-center clinical study. [2020]
12-month Healing Rates after Endodontic Therapy Using the Novel GentleWave System: A Prospective Multicenter Clinical Study. [2022]
Evaluation of Root Canal Debridement of Human Molars Using the GentleWave System. [2017]
Effectiveness of the GentleWave System in Removing Separated Instruments. [2022]
Comparative Analysis of Biofilm Removal Efficacy by Multisonic Ultracleaning System and Passive Ultrasonic Activation. [2020]
Reporting adverse events in randomized controlled trials in periodontology: a systematic review. [2018]
The dangers of dental devices as reported in the Food and Drug Administration Manufacturer and User Facility Device Experience Database. [2021]
Morbidity and mortality of major adult spinal surgery. A prospective cohort analysis of 942 consecutive patients. [2022]
Dental device-associated problems: an analysis of FDA postmarket surveillance data. [2019]
10.United Statespubmed.ncbi.nlm.nih.gov
Complications associated with PEAK PlasmaBlade from 2010 to 2020 from MAUDE. [2022]
Apical pressure created during irrigation with the GentleWave™ system compared to conventional syringe irrigation. [2022]